Ricevi le ultime notizie sulle azioni Gain Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di GANX

Ultime notizie per

GAIN THERAPEUTICS INC

Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Gain Therapeutics Inc

News

Press Releases

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

Gain Therapeutics to Participate in Upcoming Investor Conferences

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Financing

Gain Therapeutics Announces Proposed Public Offering

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Health Care

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Earnings

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

GANX

Adicet Bio

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Clene

CervoMed

Cue Biopharma

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

Immix Biopharma

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MediciNova

OS Therapies

Plus Therapeutics

Repare Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

BTIG

Roth Capital

HC Wainwright & Co.

Chardan Capital

Scotiabank

Comments

Gain Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO